ASLAN Pharmaceuticals, a Singapore biotech developing cancer therapies using the HER pathway, raised $42 million in its US initial public offering. Listed on the Taiwan Stock Exchange, ASLAN offered a downsized 6.0 million ADSs at $7.03. The company had initially filed to sell 7.5 million ADSs. At pricing, the company commands a market value of $235 million.
ASLAN Pharmaceuticals plans to list on the Nasdaq under the symbol ASLN. Leerink Partners and Piper Jaffray acted as lead managers on the deal.
